Product Description
Melt Pharmaceuticals has submitted an IND to the FDA for MELT-400 (ketamine) to treat pain. (Sourced from: https://www.meltpharma.com/melt-pharmaceuticals-submits-inds-for-melt%E2%80%91210-and-melt-400-to-fda/)
Mechanisms of Action: NMDA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Sublingual
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Melt Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Cataract
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|